A weekly dipeptidyl peptidase-4 (DPP-4) inhibitor was just as effective at controlling blood sugar in patients with type 2 diabetes as a daily DPP-4 inhibitor in a recent randomized clinical trial.
The drug, called omarigliptin, offers the prospect of a more convenient treatment for patients.
“The observed glycemic efficacy in the present study indirectly serves as further evidence of the feasibility of providing DPP-4 inhibition over the period of one week with a single once-weekly dose that is similar to that which can be achieved with daily administration,” wrote the authors of the Diabetes, Obesity and Metabolism study.
This article was adapted from information provided by Wiley.
